ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
08 Agosto 2023 - 7:34AM
Business Wire
This partnership positions Tru Niagen for
accelerated global expansion given nearly 90% of iHerb sales are
outside of the U.S.
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company
dedicated to healthy aging, announces the appointment of the
world’s number one online destination for health and wellness,
iHerb, as the newest retail partner to distribute Tru Niagen
globally. iHerb is on a mission to make health and wellness
accessible to all offering the best brands in the industry and has
established a strong international presence, with nearly 90% of
sales generated outside of the United States. iHerb has a global
audience larger than Vitacost, VitaminShoppe, and GNC combined,
proudly totaling 10 million active customers across more than 180
countries.
“Tru Niagen, backed by the highest scientific and quality
standards, is one of the most efficient NAD+ boosters on the market
and we are delighted to welcome this trusted brand to the iHerb
family,” said Lindsey Wiefels, SVP, Purchasing & House Brands
of iHerb. “Carrying the best brands in the industry is an important
key to our success and, in turn, these partnerships allow us to be
the greatest at what we do. Tru Niagen and ChromaDex exemplify
iHerb’s values as a company.”
The sole active ingredient in Tru Niagen is Niagen®, ChromaDex’s
patented nicotinamide riboside (NR) ingredient, one of the most
efficient and superior precursors of nicotinamide adenine
dinucleotide (NAD+), a coenzyme vital to cellular function. Tru
Niagen is backed by two Nobel Prize winners, 25+ human clinical
studies, 300 published scientific studies, accepted by the world’s
most rigorous regulatory bodies and is clinically proven to
increase NAD+ safely and effectively.
“NAD+ is essential for life, yet our levels decrease with age
and when we are under physiological stress,” commented Rob Fried,
CEO of ChromaDex. “Tru Niagen is the safest, most reliable, indeed
the best way to maintain high NAD+ levels and we are looking
forward to working with iHerb, the world leader in natural health
and self-care products, to make this exciting product available to
more people worldwide.”
The best-selling Tru Niagen product line including Tru Niagen
300mg 30 count, Tru Niagen 300mg 90 count, Tru Niagen 300mg 120
count, Tru Niagen Immune 150mg 30 count, and Tru Niagen 300mg Stick
Packs, for those who prefer a mix-in powder formulation, are now
available for purchase at iHerb.com.
For additional information on the science supporting Niagen®
visit www.chromadex.com and for more information on iHerb visit
www.iherb.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on NAD+ levels, of which decline
with age. ChromaDex is the innovator behind the NAD+ precursor,
nicotinamide riboside (NR), commercialized as the flagship
ingredient Niagen® and the sole active ingredient in the consumer
supplement, Tru Niagen. Nicotinamide riboside and other NAD+
precursors are protected by ChromaDex’s patent portfolio. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
About iHerb:
iHerb is on a mission to make health and wellness accessible to
all. Since our founding in 1996, we have been dedicated to offering
Earth’s best-curated selection of health and wellness products, at
the best possible value, delivered with the most convenient
experience. We believe that health and wellness should be a
universal right made possible through compassion and our collective
action. This belief will continue to guide us as we endeavor to
make our mission a reality. https://www.iherb.com/
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to global distribution.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. Risks that contribute to the uncertain nature of these
forward-looking statements include the impact of the COVID-19
pandemic on our business and the global economy; our history of
operating losses and need to obtain additional financing; the
growth and profitability of our product sales; our ability to
maintain sales, marketing and distribution capabilities; changing
consumer perceptions of our products; our reliance on a single or
limited number of third-party suppliers; and the risks and
uncertainties associated with our business and financial condition.
More detailed information about ChromaDex and the risk factors that
may affect the realization of forward-looking statements is set
forth in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230808030341/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ChromaDex (NASDAQ:CDXC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024